1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
[CAS# 1801787-56-3]

Identification

• Classification: API >> Other chemicals
• Name: 1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl]-6-oxo-4-(trifluoromethyl)-3-pyridinecarboxamide
• Synonyms: OICR 9429
• Molecular Formula: C₂₉H₃₂F₃N₅O₃
• Molecular Weight: 555.59
• CAS Registry Number: 1801787-56-3
• SMILES: CN1CCN(CC1)C2=C(C=C(C=C2)C3=CC=CC(=C3)CN4CCOCC4)NC(=O)C5=CNC(=O)C=C5C(F)(F)F

Properties

• Solubility: Very slightly soluble (0.12 g/L) (25 °C), Calc.^*
• Density: 1.325±0.06 g/cm³ (20 °C 760 Torr), Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2016 ACD/Labs)

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H315
• Safety Statements: P280

Discovery and Applications

1,6-Dihydro-N-[4-(4-methyl-1-piperazinyl)-3'-(4-morpholinylmethyl)[1,1'-biphenyl]-3-yl ]-6-Oxo-4-(trifluoromethyl)-3-pyridinecarboxamide, commonly known as DTMP, is a synthetic compound developed through medicinal chemistry research.

DTMP has pharmacological activity as a potent and selective inhibitor of specific biological targets in the human body. These targets may include enzymes, receptors, or proteins involved in disease pathways or cellular processes. DTMP has potential applications in the development of drugs for the treatment of various diseases. DTMPs can be optimized and refined through structure-activity relationship (SAR) studies to enhance their pharmacokinetic properties and therapeutic efficacy. DTMP may exhibit neuropharmacological effects due to interactions with neurotransmitter receptors or modulators in the central nervous system (CNS). This has important implications for the treatment of neurological disorders such as epilepsy, neuropathic pain or psychiatric disorders. DTMP and related compounds may have anticancer properties and potential use as chemotherapeutic agents. The molecular structure and pharmacological activity of DTMP allow its use in biochemical assays, cell-based assays, or animal models to elucidate the function of specific biological targets or pathways and to evaluate the effects of potential therapeutic interventions. DTMP and its derivatives hold promise as potential therapeutics for the treatment of diseases and conditions requiring modulation of specific biological targets. This may include neurological disorders, psychiatric disorders, cancer, inflammatory diseases, metabolic disorders or infectious diseases.

References

2022. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma. Acta Pharmacologica Sinica.
DOI: 10.1038/s41401-022-00999-z

2022. Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. Journal of Medicinal Chemistry.
DOI: 10.1021/acs.jmedchem.2c00195

2021. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. Journal of experimental & clinical cancer research : CR.
DOI: 10.1186/s13046-021-01989-5